National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company's portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company's clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.
Industry, Sector and Symbol
Industry Commercial physical research
Sub-IndustryN/A
SectorBusiness Services
Phone402-475-2525
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$119.69 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date2/11/2020 (Estimated)
OptionableNot Optionable
National Research (NASDAQ:NRC) Frequently Asked Questions
What is National Research's stock symbol?
National Research trades on the NASDAQ under the ticker symbol "NRC."
How often does National Research pay dividends? What is the dividend yield for National Research?
National Research declared a quarterly dividend on Monday, November 25th. Investors of record on Tuesday, December 31st will be given a dividend of $0.21 per share on Wednesday, January 15th. This represents a $0.84 annualized dividend and a dividend yield of 1.32%. The ex-dividend date of this dividend is Monday, December 30th. This is a positive change from National Research's previous quarterly dividend of $0.19. View National Research's Dividend History.
How were National Research's earnings last quarter?
National Research Co. (NASDAQ:NRC) released its quarterly earnings data on Tuesday, May, 7th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.31 by $0.01. The firm earned $31.48 million during the quarter, compared to analysts' expectations of $33.50 million. National Research had a net margin of 25.01% and a return on equity of 130.25%. View National Research's Earnings History.
When is National Research's next earnings date?
What is the consensus analysts' recommendation for National Research?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for National Research in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for National Research.
Has National Research been receiving favorable news coverage?
Media stories about NRC stock have trended extremely negative this week, according to InfoTrie. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. National Research earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the company's share price in the next several days. View News Stories for National Research.
Are investors shorting National Research?
National Research saw a drop in short interest during the month of November. As of November 15th, there was short interest totalling 69,400 shares, a drop of 33.2% from the October 31st total of 103,900 shares. Based on an average daily trading volume, of 50,200 shares, the short-interest ratio is presently 1.4 days. Approximately 0.5% of the company's shares are sold short. View National Research's Current Options Chain.
Who are some of National Research's key competitors?
Some companies that are related to National Research include Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), Medpace (MEDP), Intrexon (XON), Sorrento Therapeutics (SRNE), STARPHARMA HOLD/S (SPHRY), Auxly Cannabis Group (CBWTF), Luna Innovations (LUNA), Eloxx Pharmaceuticals (ELOX), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL), Bioanalytical Systems (BASI), BIOQUAL (BIOQ) and HedgePath Pharmaceuticals (HPPI).
What other stocks do shareholders of National Research own?
Who are National Research's key executives?
National Research's management team includes the folowing people:
- Steven D. Jackson, President (Age 41)
- Michael D. Hays, Chief Executive Officer, Director (Age 62)
- Kevin R. Karas, Chief Financial Officer, Senior Vice President - Finance, Treasurer, Secretary (Age 59)
- John N. Nunnelly, Lead Independent Director (Age 64)
- Donald M. Berwick M.D., Independent Director (Age 70)
- JoAnn M. Martin, Independent Director (Age 62)
- Barbara J Mowry, Independent Director (Age 69)
Who are National Research's major shareholders?
National Research's stock is owned by many different of retail and institutional investors. Top institutional investors include Conestoga Capital Advisors LLC (2.50%), State Street Corp (0.93%), Comerica Bank (0.25%), California Public Employees Retirement System (0.18%), Willis Investment Counsel (0.10%) and California State Teachers Retirement System (0.08%). Company insiders that own National Research stock include Amandla Mk Trust, Barbara Mowry, Donald M Berwick, K/I/E Trust Under Agreement 10, K/I/E/Trust Under Agreement 3/, Kevin R Karas and Steven D Jackson. View Institutional Ownership Trends for National Research.
Which institutional investors are selling National Research stock?
NRC stock was sold by a variety of institutional investors in the last quarter, including Willis Investment Counsel, Conestoga Capital Advisors LLC, Strs Ohio and Barclays PLC. Company insiders that have sold National Research company stock in the last year include Amandla Mk Trust, Barbara Mowry, Donald M Berwick, K/I/E Trust Under Agreement 10, K/I/E/Trust Under Agreement 3/, Kevin R Karas and Steven D Jackson. View Insider Buying and Selling for National Research.
Which institutional investors are buying National Research stock?
NRC stock was acquired by a variety of institutional investors in the last quarter, including First Quadrant L P CA, State Street Corp, Squarepoint Ops LLC, Virginia Retirement Systems ET AL, Comerica Bank, Nisa Investment Advisors LLC, SG Americas Securities LLC and California Public Employees Retirement System. View Insider Buying and Selling for National Research.
How do I buy shares of National Research?
Shares of NRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is National Research's stock price today?
One share of NRC stock can currently be purchased for approximately $63.57.
How big of a company is National Research?
National Research has a market capitalization of $1.58 billion and generates $119.69 million in revenue each year. The company earns $30.05 million in net income (profit) each year or $1.04 on an earnings per share basis. View Additional Information About National Research.
What is National Research's official website?
How can I contact National Research?
National Research's mailing address is 1245 Q STREET, LINCOLN NE, 68508. The company can be reached via phone at 402-475-2525.
MarketBeat Community Rating for National Research (NASDAQ NRC)
MarketBeat's community ratings are surveys of what our community members think about National Research and other stocks. Vote "Outperform" if you believe NRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
